Merck Buys British Maker Of Biotech Medicines
LINDA A. JOHNSON
TRENTON, N.J. (AP) ¿ Merck & Co. said Thursday it is making another deal in its strategy to become a top maker of biotech drugs, buying a British company that makes them.
Merck, the world's second-biggest drugmaker, said its United Kingdom subsidiary, Merck Sharp & Dohme Ltd., has agreed to acquire Avecia Biologics from its parent holding company.
Specific financial terms of the deal were not disclosed, but Merck spokesman Ian McConnell said the value is well below $1 billion.Avecia has been making small amounts of biotech drugs for use in patient tests of experimental treatments for heart disease, blood disorders and cancers for a number of companies since 1998. The drugs are "manufactured" in fermentation tanks containing rapidly reproducing cells including yeast and E. coli, with the active molecule then separated out and purified to produce medication. The company, which is based in Billingham, U.K., and employs 500 people, is making a drug for commercial sale for the first time, for client Dyax Corp. Avecia spokeswoman Bridget Hall said that drug, soon to be launched under the brand name Kalbitor, is for swelling in the extremities. Biologics, or biotech drugs, are grown in mammal, yeast or other cells rather than chemically synthesized like traditional pills. They are one of three areas that Merck, based in Whitehouse Station, N.J., is targeting for growth.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV